This schedule makes treatment easier to follow
Indeed, GLP-1RAs have evolved over time such that the frequency of dosing has decreased from twice-daily (exenatide, BD) [65], to once-daily (liraglutide, lixisenatide) [66, 67] to once-weekly (dulaglutide, exenatide QW, semaglutide) [5, 6], suggesting a higher adherence potential for the longer-acting agents (Table 2)
Its being developed by Eli Lilly and is currently in Phase 3 clinical trials for obesity and type 2 diabetes
Yet clarity about what its like to actually take these medications is in short supply
Whether youre working with GLP-related compounds, peptide blends, or single compounds, our goal is to make sourcing simple and dependable
Genua I, Cusi K